These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7652877)

  • 1. Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: single-center analysis of a 20-year period in 1600 patients.
    Hiesse C; Larue JR; Kriaa F; Blanchet P; Bellamy J; Benoit G; Charpentier B
    Transplant Proc; 1995 Aug; 27(4):2450-1. PubMed ID: 7652877
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: analysis of a 20-year period in 1600 patients.
    Hiesse C; Kriaa F; Rieu P; Larue JR; Benoit G; Bellamy J; Blanchet P; Charpentier B
    Transplant Proc; 1995 Feb; 27(1):972-4. PubMed ID: 7879250
    [No Abstract]   [Full Text] [Related]  

  • 3. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
    Gruber SA; Gillingham K; Sothern RB; Stephanian E; Matas AJ; Dunn DL
    Clin Transplant; 1994 Aug; 8(4):388-95. PubMed ID: 7949545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancers in cyclosporine-treated vs azathioprine-treated patients.
    Penn I
    Transplant Proc; 1996 Apr; 28(2):876-8. PubMed ID: 8623443
    [No Abstract]   [Full Text] [Related]  

  • 5. Single-center experience with cyclosporine therapy for kidney transplantation: analysis of a twenty-year period in 1200 patients.
    Snanoudj R; Kriaa F; Arzouk N; Beaudreuil S; Hiesse C; Durrbach A; Charpentier B
    Transplant Proc; 2004 Mar; 36(2 Suppl):83S-88S. PubMed ID: 15041313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM; Eris J; Oberbauer R; Friend P; Hutchison B; Morales JM; Claesson K; Stallone G; Russ G; Rostaing L; Kreis H; Burke JT; Brault Y; Scarola JA; Neylan JF
    J Am Soc Nephrol; 2006 Feb; 17(2):581-9. PubMed ID: 16434506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varicella-zoster infection in cyclosporine A-treated renal transplant patients.
    Lo CY; Cheng IK
    Transplant Proc; 1996 Jun; 28(3):1511-2. PubMed ID: 8658764
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ; Villa M; Laskey R; Benavides C; Schoenberg L; Welsh M; Kerman RH; Podder H; Van Buren CT; Katz SM; Kahan BD
    Clin Transplant; 2007; 21(4):460-5. PubMed ID: 17645704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten years of cyclosporine use in renal transplantation: a single-center experience with 479 renal transplants.
    Lucan M; Iacob G; Lucan C; Lăpuşan C; Munteanu A; Sîrbu S
    Transplant Proc; 2004 Mar; 36(2 Suppl):177S-180S. PubMed ID: 15041332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumors after transplantation: are there associated factors?
    Jacobs U; Paar D; Buszello H; Klehr HU
    Transplant Proc; 1996 Dec; 28(6):3248. PubMed ID: 8962258
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of antilymphocyte globulin upon the incidence of malignancies after kidney transplantation.
    Luciani J; Benalia H; Bitker MO; Mouquet C; Chartier-Kastler E; Ourhama S; Jacobs C; Chatelain C; Viars P
    Transplant Proc; 1993 Jun; 25(3):2302. PubMed ID: 8516907
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants.
    Batiuk TD; Barry JM; Bennett WM; Meyer MM; Tolzman D; Norman DJ
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1391. PubMed ID: 8382860
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term follow-up of cancer risk in patients treated with short-term cyclosporine.
    Väkevä L; Reitamo S; Pukkala E; Sarna S; Ranki A
    Acta Derm Venereol; 2008; 88(2):117-20. PubMed ID: 18311436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural history of renal function following orthotopic heart transplant.
    Al Aly Z; Abbas S; Moore E; Diallo O; Hauptman PJ; Bastani B
    Clin Transplant; 2005 Oct; 19(5):683-9. PubMed ID: 16146562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A long-term study on hyperlipidemia in stable renal transplant recipients.
    Tse KC; Lam MF; Yip PS; Li FK; Lai KN; Chan TM
    Clin Transplant; 2004 Jun; 18(3):274-80. PubMed ID: 15142048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-lymphoid cancer after liver transplantation.
    Frezza EE; Fung JJ; van Thiel DH
    Hepatogastroenterology; 1997; 44(16):1172-81. PubMed ID: 9261620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignancies under cyclosporine after kidney transplantation: analysis of a 10-year period.
    Frei U; Bode U; Repp H; Schindler R; Brunkhorst R; Vogt P; Hauss J; Pichlmayr R
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1394-6. PubMed ID: 8442152
    [No Abstract]   [Full Text] [Related]  

  • 18. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T; Kreis H; Friend P
    Clin Transplant; 2004 Aug; 18(4):446-9. PubMed ID: 15233824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
    Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoplasia in renal transplantation.
    Zúñiga V; Alvarez L; Diliz-P H
    Transplant Proc; 1996 Dec; 28(6):3332. PubMed ID: 8962294
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.